Last reviewed · How we verify
NCT03683407
Effect of Chemotherapy on TMB in NSCLC
trial testing Next-Genernation Sequence in Chemotherapy Effect in 30 participants. Status unknown.
28 February 2019
Quick facts
| Lead sponsor | Baodong Qin |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 September 2018 |
| Primary completion | 28 February 2019 |
| Estimated completion | 31 August 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Next-Genernation Sequence
Conditions studied
- Chemotherapy Effect — all drugs for Chemotherapy Effect →
- Immunotherapy — all drugs for Immunotherapy →
- Tumor Mutation Burden — all drugs for Tumor Mutation Burden →
- PD-1/L1 Inhibitor — all drugs for PD-1/L1 Inhibitor →
Sponsor
Baodong Qin — full company profile →
Who can join
Adults 18 to 75, any sex, with Chemotherapy Effect or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tumor mutation burden is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect tumor mutation burden in advanced NSCLC patients. The present study aims to evaluate whether tumor mutation burden will change after receiving chemotherapy in advanced NSCLC patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03683407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy Effect
Currently open trials in the same condition.
- NCT06525402 — Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemothe · NA · recruiting
- NCT06510010 — Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer · Phase 2 · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT05864274 — Improve Cancer-related Cognitive Impairment · NA · recruiting
- NCT06863623 — The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients · NA · recruiting
Other Baodong Qin trials
Trials by the same sponsor.
- NCT04116918 — Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC · unknown
- NCT03701607 — Effect of Chemotherapy on PD-L1 in NSCLC · unknown
- NCT03239015 — Efficacy and Safety of Precision Therapy in Refractory Tumor · Phase 2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03683407 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baodong Qin
- Last refreshed: 25 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03683407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing